Analyst consensus rating
Nautilus Biotechnology Analyst Rating: none
Direct answer
Nautilus Biotechnology's consensus rating is none.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $4.00.
Forecast evidence checked November 19, 2026.
Get free Nautilus Biotechnology email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.17
- Average price target
- $4.00
- High price target
- $4.00
- Low price target
- $4.00
- Low target gap
- +84.3%
- Target upside
- +84.3%
- High target gap
- +84.3%
- Target range width
- 0%
- Consensus rating
- none
- Analysts
- 3
- Evidence date
- November 19, 2026
- Valid through
- November 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Nautilus Biotechnology?
Nautilus Biotechnology has a verified none consensus. The same dataset has an average price target of $4.00.
How far are Nautilus Biotechnology's low and high targets from the recorded price?
The low target implies +84.3%, while the high target implies +84.3%.
How many analysts are included in Nautilus Biotechnology's consensus?
The verified consensus includes 3 analysts.
How is Nautilus Biotechnology's target upside or downside calculated?
The average target of $4.00 is divided by the recorded price of $2.17, then one is subtracted to produce +84.3%. This does not guarantee a future return.
When was Nautilus Biotechnology's analyst forecast verified?
The data was verified on 2026-11-19. The dataset is valid through 2026-11-26.